

Health Plan Coverage Report Card | March 2018

New Jersey Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in New Jersey from January 2017 through December 2017.

Key New Jersey Findings



Rejection Rate:

31%



Appeals Rate:

31%



Final Rejections:

3,489

Of health plans that received at least 200 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- Horizon BCBS NJ **62%**
- United Health Group **33%**
- Express Scripts **41%**
- Cigna Healthcare **29%**

The following had **the lowest rates of rejection:**

- Aetna **16%**
- Humana Health Plan **9%**



The following table details claims data for the New Jersey managed care organizations that received at least 200 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
Horizon BCBS NJ	62%	1,150	717
Express Scripts	41%	839	342
United Health Group	33%	1,752	579
Cigna Healthcare	29%	268	79
Independence BC East	28%	215	60
New Jersey Employees SHBP	27%	1,267	344
CVS Health	27%	1,088	290
Wellcare Management Group	19%	257	49
Aetna	16%	1,589	253
Humana Health Plan	9%	1,042	97

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

